Efficacy and safety of bevifibatide in patients with acute coronary syndrome undergoing percutaneous coronary intervention (BES-PCI): A multicenter, randomized, double-blinded, placebo-controlled, phase III trial
Year: 2025
Type: article
Language: en
Topic: Acute Myocardial Infarction Research
Authors and affiliations:
raw_author_name: Hongyi Wu
raw_affiliation_strings: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai 200032, China
raw_author_name: Lili Xu
raw_affiliation_strings: Department of Cardiology, Shanghai Geriatric Medical Center, Shanghai 200032, China
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai 200032, China
raw_author_name: Lilian Bao
raw_affiliation_strings: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai 200032, China
raw_author_name: Zhifeng Yao
raw_affiliation_strings: Department of Cardiology, Tianjin People’s Hospital, Tianjin 300121, China
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai 200032, China
raw_author_name: Xiaomei Guo
raw_affiliation_strings: Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
raw_author_name: Lin Wang
raw_affiliation_strings: Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
raw_author_name: Zhuhua Yao
raw_affiliation_strings: Department of Cardiology, Tianjin People’s Hospital, Tianjin 300121, China
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai 200032, China
raw_author_name: Qiang Tang
raw_affiliation_strings: Department of Cardiology, Shougang Hospital, Peking University, Beijing 100144, China
raw_author_name: Ying Liu
raw_affiliation_strings: Department of Cardiology, Liaoning Provincial People’s Hospital, Shenyang, Liaoning 110016, China
raw_author_name: Xiaoshu Cheng
raw_affiliation_strings: Department of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China
raw_author_name: Ying Guo
raw_affiliation_strings: Department of Cardiology, Hunan Provincial People’s Hospital, Changsha, Hunan 410005, China
raw_author_name: Shuiping Zhao
raw_affiliation_strings: Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
raw_author_name: Dongmei Wang
raw_affiliation_strings: Department of Cardiology, The 980th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army, Shijiazhuang, Hebei 050000, China
raw_author_name: Guangcheng Zhang
raw_affiliation_strings: Department of Cardiology, Jilin Provincial People’s Hospital, Changchun, Jilin 130021, China
raw_author_name: Genshan Ma
raw_affiliation_strings: Department of Cardiology, Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, China
raw_author_name: Luning Zhou
raw_affiliation_strings: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai 200032, China
raw_author_name: Juying Qian
raw_affiliation_strings: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai 200032, China
raw_author_name: Junbo Ge
raw_affiliation_strings: Department of Cardiology, Shanghai Geriatric Medical Center, Shanghai 200032, China
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai 200032, China
raw_author_name: On behalf of the BES-PCI investigators
raw_affiliation_strings: How to cite this article: Wu HY, Xu LL, Bao LL, Yao ZF, Guo XM, Wang L, Yao ZH, Tang Q, Liu Y, Cheng XS, Guo Y, Zhao SP, Wang DM, Zhang GC, Ma GS, Zhou LN, Qian JY, Ge JB; On behalf of the BES-PCI investigators. Efficacy and safety of bevifibatide in patients with acute coronary syndrome undergoing percutaneous coronary intervention (BES-PCI): A multicenter, randomized, double-blinded, placebo-controlled, phase III trial. Chin Med J 2025;XXX:1–4. doi: 10.1097/CM9.0000000000003877